Last reviewed · How we verify
Denver Infectious Disease Consultants, PLLC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Raltegravir and Abacavir/Lamivudine | Raltegravir and Abacavir/Lamivudine | marketed | Antiretroviral combination (INSTI + NRTI) | HIV integrase, HIV reverse transcriptase | Infectious Disease / Virology |
Therapeutic area mix
- Infectious Disease / Virology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Charlotte-Paige Rolle, MD · 1 shared drug class
- Fundacion SEIMC-GESIDA · 1 shared drug class
- Fundação Bahiana de Infectologia · 1 shared drug class
- Hospitales Universitarios Virgen del Rocío · 1 shared drug class
- Saint Michael's Medical Center · 1 shared drug class
- The University of Texas Health Science Center, Houston · 1 shared drug class
- ViiV Healthcare · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Denver Infectious Disease Consultants, PLLC:
- Denver Infectious Disease Consultants, PLLC pipeline updates — RSS
- Denver Infectious Disease Consultants, PLLC pipeline updates — Atom
- Denver Infectious Disease Consultants, PLLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Denver Infectious Disease Consultants, PLLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/denver-infectious-disease-consultants-pllc. Accessed 2026-05-17.